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SUMMARY – The aim of this study was to determine the relative prevalence and clinical cha-
racteristics of patients with pure menstrual migraine (PMM) and menstrually related migraine 
(MRM), and to compare them with the women free of it in an outpatient clinic-based population. 
Adult menstruating women with IChD-2 migraine were included. Demographic data were obta-
ined by verbal report. Study women were asked to keep a headache diary for 6 months, in which 
they recorded information on headache characteristics, medication use and presence of menses. Iron 
deficiency anemia was considered to be present if the patient had received therapy for iron deficiency  
anemia or laboratory tests indicated low iron and/or hemoglobin levels (within one year). A total 
of 289 women were included, 52 (18.0%) with PMM and 116 (40.1%) with MRM, whereas 121 
(41.9%) women had not observed any relationship between migraine and their menstrual cycle (non-
MM). Duration of migraine attacks was longer in PMM/MRM patients (p<0.0001). No significant 
difference was observed according to other migraine-associated symptoms. women with PMM/
MRM took significantly more tryptans (p<0.0001) and iron deficiency anemia was significantly 
more common in women with PMM/MRM (p=0.008). In conclusion, this study supported earlier 
findings that PMM/MRM has similar clinical characteristics as non-MM, except for longer dura-
tion. In addition, iron deficiency anemia is more common in women with PMM/MRM, which may 
be an underlying mechanism aggravating migraine attacks.  
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Introduction
Relationship between female hormones estrogen 
and progesterone and migraine is well known1-3. Ac-
cording to clinical observations and International 
Classification of headache Disorders (IChD-2) Ap-
pendix, migraine attacks that occur in a consistent re-
lationship with menstruation, regularly ± 2 days from 
the onset of menstruation but do not occur at other 
times during menstrual cycle can be classified as pure 
menstrual migraine without aura and as menstrually-
related migraine without aura if other attacks occur 
throughout the month4. Approximately 33%-60% 
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of women have menstrually related migraine attacks 
(MRM), while 7%-9% of women have pure menstru-
al migraine (PMM)1,5-10.
Clinical observations suggest that MRM attacks 
are usually more severe, of longer duration and more 
resistant to treatment11-14. Pure menstrual migraine 
typically improves during pregnancy, mainly during 
the second and third trimesters, probably due to the 
constant level of the hormone estrogen15. 
The aim of this study was to determine the relative 
prevalence and clinical characteristics of patients with 
PMM and MRM, and to compare them with women 
without it in a cohort of women presenting to an out-
patient headache clinic. 
Patients and Methods
This was an outpatient clinic-based population 
study evaluating the relative prevalence and clinical 
characteristics of PMM and MRM. Migraine was 
diagnosed according to the IChD-2 criteria for mi-
graine with or without aura4. Patients were included 
randomly and all gave their informed consent for 
participating in the study. The study was approved 
by the Research Ethics Committee. All patients had 
episodic migraine. Patients attending the outpatient 
headache clinic at our University Department of 
Neurology were asked to keep a headache diary for 6 
months (observation period), in which they recorded 
data on headache characteristics: frequency, dura-
tion, migraine associated symptoms, medication us-
age and presence of menses. All patients were taking 
acute treatment for migraine, analgesics or tryptans. 
None of the patients was on prophylactic therapy and 
there was no analgesic overuse recorded. Patients were 
screened for comorbidities; iron deficiency anemia 
(IDA) was considered to be present when confirmed 
by the patient, receiving treatment for iron deficiency 
anemia within a year and laboratory tests indicating 
low iron and/or hemoglobin levels (within one year). 
The diagnosis of iron deficiency  anemia was not based 
on the best practice guidelines for diagnosing and 
managing of iron deficiency  anemia16 because it was 
not the primary point of the present study. 
Study patients were categorized as follows: (a) mi-
graine attacks occur only perimenstrually and at no 
other times during the month; (b) migraine attacks 
occur always perimenstrually and also at other times 
during the month; (c) migraine attacks occur occa-
sionally but not always in relation with menstruation; 
and (d) migraine attacks never occur perimen-
strually. 
Data were compared between those with 
PMM (group a), /MRM (groups b and c) and 
those without (group d). 
Statistical analysis
On statistical analysis, χ2-test and Fisher exact 
test were used for comparison of proportion, mean 
and standard deviation for description of continuous 
variables, and Student’s t-test for comparison between 
different groups. STATISTICA 6.0 (StatSoft Inc., 
Tulsa, OK, USA) was used for analysis. The level of 
significance was set at p<0.05.
Results
Data on 289 patients were analyzed. The mean 
age of patients was 39.9±12.3 years, all Caucasians. 
Data analysis showed the following: migraine at-
tacks occurred only perimenstrually and at no other 
times during the month in 52 (18.0%) women (group 
a); migraine attacks occurred always perimenstrually 
and also at other times during the month in 21 (7.3%) 
women (group b); migraine attacks occurred occa-
sionally but not always in relation with menstruation 
in 95 (32.9%) women (group c); and migraine attacks 
never occurred perimenstrually in 121 (41.9%) women 
(group d). 
According to the proposed criteria, in our group 
of patients pure menstrual migraine was present in 52 
(18.0%) women. The women reporting that they had 
not observed a clear pattern of migraine attacks al-
ways perimenstrually but only occasionally were cat-
egorized in group c, meaning that they experienced 
an attack in at least 2 of 3 menstrual cycles and ad-
ditionally at other times of the cycle. Therefore, in our 
study population, MRM was present in 116 (40.1%) 
women.  
The women with PMM or MRM differed signifi-
cantly from those whose attacks were not related to 
menstruation (non-menstrual migraine, non-MM) 
in the following: 1) the group of PMM women was 
older than non-MM group: mean age 43.1±11.2 vs. 
39.3±12.3 (p=0.043); 2) duration of migraine attacks 
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was longer in the PMM group: 1-3 days in 67.3% 
(PMM) vs. 37.1% (non-MM) and more than 3 days 
in 17.3% (PMM) vs. 6.9% (non-MM) (p<0.0001); 
3) nausea with or without vomiting was significant-
ly more common in non-MM group: 57.5 vs. 36.5% 
(PMM) (p=0.0014); 4) women with PMM were tak-
ing significantly more triptans: 61.5 vs. 30.2% (non-
MM) (p=0.0001); 5) women with non-MM were 
taking more simple analgesics or NSAIDs: 66.6% vs. 
36.5% (PMM) (p=0.0001); and 6) IDA was signifi-
cantly more common in women with PMM: 38.5% 
vs. 22.9% (non-MM) (p=0.008). 
There was no significant difference between pa-
tients with PMM/MRM and non-MM according to 
localization, intensity and quality of pain, laterality of 
headache pain, presence of photophobia, phonopho-
bia and osmophobia. Clinical characteristics of pa-
tients with PMM/MRM and non-MRM are shown 
in Table 1. 
Discussion 
A normal hormonal cycle in women’s life has sev-
eral important points that may influence the occur-
rence or change in the character of migraine: menar-
che, pregnancy, use of contraception, menopause and 
use of hormone replacement therapy1. before puberty, 
the prevalence of migraine does not significantly dif-
fer between girls and boys, however, in adolescence, 
the incidence and prevalence of migraine increases 
more rapidly in girls. Migraine usually begins to oc-
cur in the second decade and its prevalence decreases 
after the fourth decade; it is believed to be influenced 
largely by female hormones15,17,18. 
It is believed that the primary trigger for men-
strual migraine is the decrease in estrogen level15. Es-
trogens and progestins have a significant influence on 
central serotoninergic and opioid neurons, modulat-
ing neuronal activity and receptor thickness. based on 
experimental studies, the decrease in estrogen levels 
just before the onset of menstruation leads to disorder 
of homeostatic gene regulation and hyperexcitabil-
ity of cell membranes, which sensitizes the neurons 
to triggers, thus leading to the activation of migraine 
attack. In the interictal phase when the level of estro-
gen is highest, the increased neuronal excitability is 
balanced by homeostatic gene regulation in cerebral 
cortex and nociceptive systems19. Due to stable (i.e. 
increased) estrogen levels in pregnancy, the frequency 
of migraine decreases. The frequency of migraine in-
creases postpartum and in some women during the 
pause of taking oral contraceptives; these are periods 
when the level of estrogen in the woman’s body de-
creases20. 
The results of our study showed that PMM oc-
curred in 18% of patients with migraine and MRM 
was present in 40.1% of women. Our results are com-
parable to similar studies in which the prevalence of 
PMM was also investigated in patients at-
tending headache clinics and is reported 
to be 26%-60%21. Approximately 60% of 
women have migraine attacks more fre-
quently during menstruation, while 7%-
9% of women have migraine attacks only 
during menstruation5,6. A study in The 
Netherlands established a prevalence of 
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table 1. clinical characteristics of patients 
with pure menstrual migraine (pMM) and 
menstrually related migraine (MRM) vs. 
non-MRM patients
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Typical clinical characteristics of migraine are more 
pronounced in the 30-49 age group, while less typical 
ones are present in younger and older age groups that 
can also be in part influenced by the change in hor-
mone status22. PMM has a number of clinical charac-
teristics in common with other types of migraine and 
is typically not related to aura1,23. Although the major-
ity of studies found the attacks in menstrual migraine 
to be more severe, of longer duration, more resistant to 
therapy and associated with more functional disabil-
ity1,11,24,25, some studies showed small differences be-
tween the attacks of menstrual migraine and attacks 
in other periods of the menstrual cycle9. In our study, 
the duration of migraine attacks in patients with men-
strual migraine was longer, lasting one to three days or 
more; however, nausea with or without vomiting was 
frequently or rarely present as compared with patients 
with non-MM who reported a significantly higher 
rate of nausea and vomiting. In our study, significantly 
more women with PMM were taking triptans for the 
treatment of migraine attacks, possibly reflecting the 
fact that their headaches were more disabling. 
Anemia is considered to aggravate and be a cause 
of headache; our study showed that iron deficiency 
anemia was significantly more common in women 
with PMM. Low iron levels may be due to mechani-
cal hemolysis, intestinal bleeding, hematuria, sweat-
ing, low iron intake or poor intestinal absorption26; 
patients included in our study did not suffer from any 
of chronic diseases that would cause iron deficiency 
anemia. women of childbearing age are at an espe-
cially high risk of iron deficiency due to ongoing men-
strual blood losses. Findings from our study suggest 
that iron deficiency anemia, found to be more com-
mon in patients with menstrual migraine, may con-
tribute to the severity and duration of headache in 
these patients. It is easily evaluated and treated, but 
often remains undiagnosed. The optimal diagnostic 
approach is to measure serum ferritin as an index of 
iron stores and serum transferrin receptor as an index 
of tissue iron deficiency16,26. 
Although anemia is considered to aggravate head-
aches, we found no clinical studies in the literature 
that prove the relationship between migraine, particu-
larly menstrual migraine, and iron deficiency anemia. 
In this study, we only screened for comorbidities and 
did not perform additional diagnostic tests if iron de-
ficiency was noted. Since our study was not designed 
to prove such a relationship, we did not perform ad-
ditional clinical tests. post-hoc analysis revealed the 
possible relationship between iron deficiency anemia 
and PMM/MRM. 
Anemia may be treated by preventing decreased 
iron stores through a balanced food intake or iron 
supplements. The treatment of iron deficiency should 
always be initiated with oral iron. when this fails 
because of large blood losses, iron malabsorption, or 
intolerance to oral iron, parenteral iron can be given 
using iron dextran, iron gluconate or iron sucrose26.
Menstrual migraine is often related to dysmen-
orrhea, and can be related to other somatic changes 
that precede menstruation like nausea, low back pain, 
breast sensitivity, and cramps, which is the conse-
quence of decrease in the level of hormones1; however, 
we found no literature report on the relationship be-
tween iron deficiency anemia and PMM/MRM. This 
might be explained by the relationship between dys-
menorrhea, menstrual migraine and iron deficiency 
anemia, although the present study was not intended 
to prove such a relationship. 
PMM is in some cases unrecognized. Keeping a 
diary for at least 3 months is an efficient way to di-
agnose PMM27. Patient diaries that record headache 
onset and relationship to the menstrual cycle will 
allow for accurate prediction of the onset of PMM; 
this information is also needed to decide on timing 
of intermittent preventive therapy. In women with 
regular menstrual cycle, a short prophylaxis 3-4 days 
before the anticipated onset of menstruation can be 
recommended, usually with non-steroid antirheumat-
ic drugs, tryptans, or ergotamine derivatives, and in 
some cases percutaneous estrogen patch gel28-31. 
This study suffered from some limitations, as it 
was not designed as a cross sectional population-based 
study and the diagnosis of iron deficiency anemia was 
not based on the best practice guidelines for diag-
nosing and managing iron deficiency anemia. It was 
post hoc analysis that revealed a possible relationship 
between iron deficiency anemia and PMM/MRM. 
Therefore, we did not perform additional laboratory 
tests to compare the PMM/MRM group with non-
MM group in order to elucidate the pathophysiology 
of iron deficiency anemia in PMM patients. These is-
sues need further evaluation in another study. 
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Conclusions
Results of this study showed that migraine related 
to menstrual cycle to be present in a relatively large 
number of fertile women. In this cohort of patients 
referred to a specialist headache clinic, pure menstrual 
migraine was present in 18% of patients, while ad-
ditional 40% had menstrually-related migraine. Re-
sults of our study are in line with clinical observations 
that menstrual migraines are of longer duration but 
we could not confirm them to differ in other clinical 
characteristics from non-menstrual migraines. Inter-
estingly, our results showed iron deficiency anemia to 
be significantly more common in women with men-
strual migraine; this observation needs to be further 
validated. In guidelines for the treatment of primary 
headaches, iron deficiency anemia is not mentioned 
as an important factor that physicians should check 
for. Therefore, we suggest that iron deficiency anemia 
be looked for in patients with menstrually related mi-
graines and appropriately treated. we hope that the 
results of our study will open new research perspec-
tives in the field.
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Sažetak
JE LI ANEMIJA ZbOG NEDOSTATKA ŽELJEZA POvEZANA S MENSTRUALNOM MIGRENOM? – 
post hoc ANALIZA OPSERvACIJSKE STUDIJE ZA PROCJENU KLINIčKIh ZNAčAJKA bOLESNICA 
S MENSTRUALNOM MIGRENOM
V. Vuković-cvetković, D. plavec, A. Lovrenčić-huzjan, I. Galinović, V. Šerić i V. Demarin
Cilj ove studije bio je utvrditi relativnu učestalost i kliničke značajke bolesnica s isključivo menstrualnom migrenom 
(IMM) i mentrualno povezanom migrenom (MPM) u odnosu na ostale bolesnice s migrenom. U studiju su bile uključene 
žene reprodukcijske dobi s migrenom prema kriterijima IChD-2. Sudionice su zamoljene da vode dnevnik glavobolja 
tijekom 6 mjeseci u koji su zapisivale karakteristike glavobolja, lijekove koje su uzimale i datume menstruacije. Siderope-
nična anemija je evidentirana ako su laboratorijski testovi u posljednjih godinu dana ukazivali na niske razine željeza i/ili 
hemoglobina. U studiju je bilo uključeno 289 žena, 52 (18,0%) s IMM i 116 (40,1%) s MPM, dok 121 (41.9%) žena nije 
primijetila povezanost između migrene i menstrualnog ciklusa (ne-MM). Trajanje migrenskih napadaja je bilo duže kod 
bolesnica s IMM/MPM (p<0,0001). Nije zabilježena značajna razlika u odnosu na druge prateće simptome migrenske 
glavobolje. Žene s IMM/MPM značajno su češće uzimale triptane (p<0,0001). Sideropenična anemija bila je značajno 
češća kod žena s IMM/MPM (p=0,008). Zaključeno je kako uz duže trajanje glavobolja žene s IMM/MPM imaju i druge 
slične kliničke značajke kao i ne-MM. Također, sideropenična anemija bila je češća kod žena s IMM/MPM, što može biti 
potencijalni mehanizam koji pogoršava migrensku glavobolju. 
Ključne riječi: Migrenske bolesti – etiologija; Migrenske bolesti – fiziopatologija; Anemija, željezo – nedostatak; Menstruacij-
ski ciklus; Estrogeni - metabolizam
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